Home›Trial›NCT04395677
🔬NCT04395677Phase 2ACTIVE NOT RECRUITING

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

Study Summary

The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC.

Conditions
Non Small Cell Lung Cancer
Interventions / Drugs
AB-106
View on ClinicalTrials.gov ↗
Sponsor
NUVB
Nuvation Bio
Oncology
B69/100
Study Details
Enrollment173 participants
Primary Completion—
Lead SponsorNuvation Bio Inc.
Data Retrieved2026-04-11 04:23:06.088453+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.